Navigation Links
TomoTherapy Concludes Treatment Quality Challenge
Date:7/1/2008

TomoTherapy Incorporated (NASDAQ:TOMO), maker of the TomoTherapy® Hi·Art® treatment system for advanced radiation therapy, today announced the close of its Treatment Quality Challenge. The company had offered $250,000 to any U.S. cancer center that could surpass the quality of a helical TomoTherapySM treatment plan using a single-rotation Varian RapidArc™ plan delivered in two minutes or less. The three-month program ended on June 30, 2008, without a single entry.

MADISON, Wis. (Business Wire EON) July 1, 2008 -- "For TomoTherapy, the Challenge was a definite success," said Del Coufal, TomoTherapy's vice president of marketing. "It generated strong support from customers and gave us the opportunity to let new audiences know that our focus is, first and foremost, on improving the quality of cancer care."

Since its clinical introduction in 2003, the TomoTherapy Hi·Art treatment system has emerged as the gold standard for image-guided, intensity-modulated radiation therapy (IG-IMRT). The system is unique among linear accelerators because it was built on a CT scanner platform, thereby integrating true CT imaging with continuous, 360-degree delivery of targeted radiation.

"Our platform has changed the way cancer centers think about radiation therapy," said Fred Robertson, CEO of TomoTherapy. "It's no longer just about patient throughput as a function of beam-on time. It's about efficiencies to be gained across the clinical workflow with a single integrated system. And, it's about new opportunities to enhance the quality of life for cancer patients."

Robertson points to TomoTherapy's CTrue™ imaging: "More than 95 percent of patients who undergo treatment on our machines are CT scanned before each and every daily treatment. Though it does add minimal time to the process, our customers use this feature because it improves accuracy—and they can still treat more than 30 patients per day. This unique combination of unmatched quality and overall system efficiency is the true power of our platform."

As the Hi·Art system continues to mature, Coufal said there are several industry-leading innovations on the horizon. 'We expect to see improvement in overall patient throughput with an exciting new product moving through our development pipeline. It will be especially useful for the more routine case types. With this and future advances, it is clear that our next-generation, ring gantry platform can offer all the flexibility cancer centers demand."

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2008 TomoTherapy Incorporated. All rights reserved. TomoTherapy, CTrue, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Medical Manufacturer TomoTherapy Implements SAP Solution in Only 16 Weeks
2. MUSCs Hollings Cancer Center, Ralph H. Johnson VA Medical Center Partner on New TomoTherapy Treatment for Cancer Patients
3. NIH study concludes next weeks summer chorus camp for seniors improves quality of life
4. Children in non-English-speaking households face many health disparities, researcher concludes
5. Global menopause summit concludes HRT is safe for healthy women entering menopause
6. Study concludes no racial disparities in long-term outcomes in recipients of liver transplants
7. Broad Stakeholder Coalition Concludes that the Pathway for Biosimilars Act Fails to Ensure Timely Access to Safe, Affordable Biogeneric Medicines for Patients
8. Government Concludes Vaccines Caused Autism
9. Phyhealth Concludes $1.5 Million Financing for Launch of Its Pilot Community-Based HMO
10. Dblur Concludes Licensing Deal With STMicroelectronics
11. Journal Sleep: Study concludes a daytime nap can benefit a persons memory performance
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 TomoTherapy Concludes Treatment Quality Challenge 
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids ... Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, ... run is geared towards children of all ages; it is a non-competitive, non-timed event, ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... ... , ... HMP , a leader in healthcare events and education, today announced ... Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie ... competition recognizes editorial and design excellence across a range of sectors. This year’s program ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
Breaking Medicine Technology: